Molecular structure of ATRA-BA Hybrid
ATRA-BA Hybrid
Alternate Names:
4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate
Application:
ATRA-BA Hybrid is a differentiation inducer and HDAC inhibitor prodrug
Purity:
≥95%
Molecular Weight:
476.7
Molecular Formula:
C31H40O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ATRA-BA Hybrid is the combination of a differentiation-inducer all-trans-Retinoic Acid and the HDAC inhibitor Butyric Acid that have been incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to help their cellular uptake and to better synergize their cancer killing efficiency.
ATRA-BA Hybrid References
Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.R: 22-36/37/38-63; S: 22-26-36-45
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ATRA-BA Hybrid, 25 mg | sc-221275 | 25 mg | $340.00 |